Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice

Atherosclerosis

Volumn 168, Issue 2, 2003, Pages 229-237

  Garber, David W ^a   Handattu, Shaila ^a   Aslan, Ibrahim ^a   Datta, Geeta ^a   Chaddha, Manjula ^a   Anantharamaiah, G M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Atherosclerosis; Lipoproteins; Proteoglycans

Indexed keywords

ACETYLLEUCYLARGINYLLYSYLLEUCYLARGINYLLYSYLARGINYLLEUCYLLEUCYLARGINYLASPA RTY LTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMINY LLYSYLLEUCYLLYSYLGLUTAMINYLALANYLPHENYLALANINAMIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARGININE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; INTERMEDIATE DENSITY LIPOPROTEIN; IODINE 125; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; POLYPEPTIDE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; FEMALE; FOOD COMPOSITION; HYPOCHOLESTEROLEMIC ACTIVITY; KNOCKOUT MOUSE; LIVER; METABOLIC CLEARANCE RATE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOACTIVITY; STRAIN DIFFERENCE;

EID: 0038511964     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00101-1     Document Type: Article

References (21)

1. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1999;1-16.
2. Mahley RW. 1988. Apolipoprotein E: cholesterol transport protein with expanding cell biology, Science 1998;240:622-30.
3. Zeng B.-I., Mortimer B.C., Martins I.J., Seydel U., Redgrave T.G. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 39:1998;845-860.
4. Innerarity T.L., Hui D.Y., Mahley R.W. Hepatic apolipoprotein E (remnant) receptor. Noseda G., Fragiacomo Fumagalli S.R., Paoletti R. Lipoproteins and coronary atherosclerosis. 1982;173-181 Amsterdam:Elsevier, North Holland.
5. Goldstein J.L., Basu S.K., Brown M.S. Receptor-mediated endocytosis of low density lipoprotein in cultured cells. Methods Enzymol. 98:1983;241-260.
6. Obunike J.C., Pillarisetti S., Deckelbaum R.J., Goldberg I.J. The heparin-binding protein apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler. Thromb. Vasc. Biol. 20:2000;111-118.
7. Zaiou M., Arnold K.S., Newhouse Y.M., Innerarity T.L., Weisgraber K.H., Segall M.L., Phillips M.C., Lund-Katz S. Apolipoprotein E-low density lipoprotein receptor interaction: influences of basic residue and amphipathic α-helix organization in the ligand. J. Lipid Res. 41:2000;1087-1095.
8. Fan J., Ji Z.-S., Huang Y., DeSilva H., Sannan D., Mahley R.W., Innerarity T.L., Taylor J.M. Increased expression of apo E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J. Clin. Invest. 101:1998;2151-2164.
9. Datta G., Chaddha M.C., Garber D.W., Chung B.H., Tytler E.M., Dashti N., Bradley W.A., Gianturco S.H., Anantharamaiah G.M. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry. 39:2000;213-220.
10. Datta G., Garber D.W., Chung B.H., Chaddha M., Dashti N., Bradley W.A., Gianturco S.H., Anantharamaiah G.M. Cationic domain 141-150 of apo E covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J. Lipid Res. 42:2001;959-966.
11. Anantharamaiah G.M., Jones J.L., Brouillette C.G., Schmidt C.F., Chung B.H., Hughes T.A., Bhown A., Segrest J.P. Studies of synthetic peptide analogs of the amphipathic helix. J. Biol. Chem. 260:1985;10246-10255.
12. Anantharamaiah G.M. Synthetic peptide analogs of apolipoproteins. Methods Enzymol. 128:1986;627-647.
13. Mishra V.K., Palgunachari M.N., Lund-Katz S., Phillips M.C., Segrest J.P., Anantharamaiah G.M. Effect of arrangement of tandem repeating units of class A amphipathic α helixes on lipid interaction. J. Biol. Chem. 270:1995;1602-1611.
14. Bilheimer D.W., Eisenberg S., Levy R.I. The metabolism of very low density lipoprotein proteins: I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260:1972;212-221.
15. Paigen B., Ishida B.Y., Verstuyft J., Winters R.B., Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 10:1990;316-323.
16. Plump A.S., Scott C.J., Breslow J.L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:1994;9607-9611.
17. Garber D.W., Venkatachalapathi Y.V., Gupta K.B., Ibdah J., Phillips M.C., Hazelrig J.B., Segrest J.P., Anantharamaiah G.M. Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats: correlation with physical properties. Arterioscler. Thromb. 12:1992;886-894.
18. Garber D.W., Kulkarni K.R., Anantharamaiah G.M. A sensitive and convenient method for lipoprotein profile analysis of individual mouse samples. J. Lipid Res. 41:2000;1020-1026.
19. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
20. Garber D.W., Datta G., Chaddha M., Palgunachari M.N., Hama S.Y., Navab M., Fogelman A.M., Segrest J.P., Anantharamaiah G.M. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42:2001;545-552.
21. Slotte J.P. Lateral domain heterogeneity in cholesterol/phosphatidylcholine monolayers as a function of cholesterol concentration and phosphatidylcholine acyl chain length. Biochim. Biophys. Acta. 1238:1995;118-126.